NES and myeloproliferative disorder: Progeroid mice were chronically treated with a β3-AR agonist, which can rescue nestin+ niches in humans and mice with age-related myeloproliferative disorders (Arranz et al., 2014, Drexler et al., 2019) and has been recently suggested to rejuvenate normally aged HSCs (Maryanovich et al., 2018).